Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FH-Deficient RCC”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Not applicableUnknownNCT05243173
What this trial is testing

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

Who this might be right for
MetabolomicsRenal Cell CarcinomaFH-Deficient RCC+1 more
RenJi Hospital 100
Not applicableUnknownNCT05535829
What this trial is testing

Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients

Who this might be right for
FH-Deficient RCCSystemic TreatmentsBiomarkers
RenJi Hospital 100
Testing effectiveness (Phase 2)Study completedNCT04068831
What this trial is testing

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell CarcinomaFumarate Hydratase Deficient Renal Cell CarcinomaSuccinate Dehydrogenase Deficient Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Testing effectiveness (Phase 2)UnknownNCT04146831
What this trial is testing

Sintilimab in FH-deficient Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaFH-deficientSintilimab
West China Hospital 37
Testing effectiveness (Phase 2)UnknownNCT05877820
What this trial is testing

Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

Who this might be right for
Fumarate Hydratase Deficient Renal Cell Carcinoma
RenJi Hospital 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04387500
What this trial is testing

Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal CellFumarate Hydratase DeficiencyImmunotherapy
West China Hospital 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03635892
What this trial is testing

Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced or Metastatic Non-clear Cell Renal Cell CarcinomaUnclassified Renal Cell CarcinomaPapillary Renal Cell Carcinoma+4 more
Memorial Sloan Kettering Cancer Center 60